What is Mayne Pharma Group Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Mayne Pharma Group's annualized net income for the quarter that ended in Dec. 2024 was A$-51.1 Mil. Mayne Pharma Group's average shareholder tangible equity for the quarter that ended in Dec. 2024 was A$-124.2 Mil. Therefore, Mayne Pharma Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was N/A%.
The historical rank and industry rank for Mayne Pharma Group's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, Mayne Pharma Group's highest Return-on-Tangible-Equity was 190.70%. The lowest was -200.93%. And the median was -65.03%.
ASX:MYX's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.655 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Mayne Pharma Group Return-on-Tangible-Equity Historical Data
The historical data trend for Mayne Pharma Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Mayne Pharma Group Return-on-Tangible-Equity Chart
Competitive Comparison of Mayne Pharma Group's Return-on-Tangible-Equity
For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Mayne Pharma Group (ASX:MYX) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Mayne Pharma Group Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Mayne Pharma Group's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:MYX has been successfully added to your 